Jennifer A Chan
Alliance for Clinical Trials in Oncology · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jennifer A Chan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:07 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03375320 · Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI) · active not recruiting · Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm · principal investigator
- Ph2NCT02795858 · A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsDana-Farber Cancer Institute · completed · Carcinoid Tumors · principal investigator
- N/ANCT00831571 · Prospective Analysis of Hypersensitivity Reactions to OxaliplatinDana-Farber Cancer Institute · completed · Colorectal Cancer, Esophageal Cancer, Gastric Cancer · principal investigator
- Ph2NCT00130689 · Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric CancerDana-Farber Cancer Institute · completed · Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Proteoglycans Modulate Sonic Hedgehog RseponsesK08HD048595 · NICHD · DANA-FARBER CANCER INST · fiscal years 2005 to 2006 · $90,377 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03375320
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:07 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.Oncologist · 2014326 citationsRCR 8.8
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.J Clin Oncol · 2009260 citationsRCR 5.1
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.N Engl J Med · 2025148 citationsRCR 44.0
- Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Lancet Oncol · 2015101 citationsRCR 3.6
- 65 citationsRCR 2.1
- A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.Endocr Relat Cancer · 201332 citationsRCR 0.9